Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 364

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 364
---
 from DTC was executed in a phased and structured manner: • Closure of E -Commerce Operations.We began a gradual wind -downof our e -commercechannel in early 2025, including removing the ability to place new orders directly through our platform. While customers could no longer purchase products directly, existing users continued to have access to our services. • Customer Support Continuity.Existing DTC customers received full product support to complete their user journey, including access to our digital platform and consultations with certified genetic nutritionists, until all obligations were fully met. • Reallocation of Resources.We eliminated or reassigned resources to align more closely with the B2B2C model, ensuring operations better supported the transition. • Product Development.We communicated the operational changes to stakeholders and began working with potential B2B2C partners to map out the new customer journey and refine the experience. While discussions with potential partners have been initiated, we have not yet entered into any formal commercial agreements under the new model, which remains in development. Nonetheless, we believe that the B2B2C model will facilitate more efficient scaling with lower operational costs, broader geographic reach, and deeper market penetration through trusted local partners. 180 Our Operating Segments We operate across two segments within our corporate structure, dedicated to providing precise and secure biological data to empower individuals to make informed health choices. Our business units operate at the forefront of scientific development, genetic testing and will be integrated with AI -driventechnology, designed to address the entire spectrum of healthcare needs, spanning prevention diagnosis and prognosis, integrating a wide range of clinical, biological, and lifestyle data. The services within these segments have been developed based on our experience in Latin America, allowing us to adapt our tests and results based on local language and specific needs. With a focus on precision, privacy, and accessibility, OmnigenicsAI is committed to empowering individuals and healthcare providers with the tools necessary for proactive health management through the following categories with its current brands: • Rewell: personalized wellness and preventative health solutions that integrate genetic, microbiome and lifestyle data, with nutrigenetic guidance tailored to each user. Through our digital platform, users access DNA and gut microbiome testing, paired with personalized health recommendations designed to empower individuals in making informed health decisions, particularly for chronic disease prevention and gut health. Initially distributed as a direct -to-consumerproduct, in 2025, we expect to transition the distribution of Rewell to a business -to-business-to-consumerdistribution model. Rewell’s services include consultations with